Literature DB >> 15222636

Serum matrix metalloproteinase-9 is elevated in men with a history of myocardial infarction.

J Renko1, A Kalela, O Jaakkola, S Laine, M Höyhtyä, H Alho, S T Nikkari.   

Abstract

Elevated serum inflammatory markers have been reported in coronary heart disease. Levels of serum matrix metalloproteinase-9 (MMP-9), C-reactive protein (CRP), C3-complement (C3) and autoantibodies against oxidized low-density lipoprotein (oxLDL) in 120 male subjects with a history of myocardial infarction (MI) were compared with those in 250 age-matched controls, both groups from a large cross-sectional population survey, the FINRISK study. The concentrations of serum MMP-9 and autoantibodies against oxLDL were measured by enzyme-linked immunosorbent assay, CRP and C3 by immunonephelometry. MMP-9, CRP and C3 concentrations were higher in the subjects with a history of MI than in the controls (p=0.037, p=0.004, and p=0.006, respectively). There was no difference between the groups in serum levels of autoantibodies against oxLDL. In other background characteristics, men in the MI group had higher body mass index (BMI) and serum triglyceride values and lower serum HDL cholesterol values compared to controls (p=0.009, p=0.001, and p<0.001, respectively). When analyzed by stepwise multiple logistic regression using BMI, HDL cholesterol, triglycerides, CRP, C3 and MMP-9 as independent variables, the significant predictors for MI were HDL cholesterol (p=0.002) and MMP-9 (p=0.015). These results suggest that increased serum MMP-9 may reflect inflammatory pathologic processes that are related to progression of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15222636     DOI: 10.1080/00365510410006054

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  6 in total

1.  Physiological matrix metalloproteinase concentrations in serum during childhood and adolescence, using Luminex Multiplex technology.

Authors:  Kathryn M Thrailkill; Cindy S Moreau; Gael Cockrell; Pippa Simpson; Rajiv Goel; Paula North; John L Fowlkes; Robert C Bunn
Journal:  Clin Chem Lab Med       Date:  2005       Impact factor: 3.694

2.  Matrix metalloproteinases in cerebral ischemia.

Authors:  Hahn Young Kim; Seol-Heui Han
Journal:  J Clin Neurol       Date:  2006-09-20       Impact factor: 3.077

Review 3.  Matrix metalloproteinases and myocardial infarction.

Authors:  Wannakorn Phatharajaree; Arintaya Phrommintikul; Nipon Chattipakorn
Journal:  Can J Cardiol       Date:  2007-07       Impact factor: 5.223

4.  Lysophosphatidic Acid Is Associated with Atherosclerotic Plaque Instability by Regulating NF-κB Dependent Matrix Metalloproteinase-9 Expression via LPA2 in Macrophages.

Authors:  Chun Gu; Fang Wang; Zhenwen Zhao; Hongyue Wang; Xiangfeng Cong; Xi Chen
Journal:  Front Physiol       Date:  2017-04-27       Impact factor: 4.566

5.  Oxidative/Antioxidative Status in Patients after Myocardial Infarction and in Those without Cardiovascular Event Depending on Anthropometric Factors Defining Body Weight.

Authors:  Grzegorz Józef Nowicki; Barbara Ślusarska; Andrzej Prystupa; Maciej Polak; Maria Czubaj-Kowal; Ewa Rudnicka-Drożak
Journal:  Int J Environ Res Public Health       Date:  2019-10-23       Impact factor: 3.390

6.  Dose-Dependent Inhibitory Effect of Rosuvastatin in Japanese Patients with Acute Myocardial Infarction on Serum Concentration of Matrix Metalloproteinases-INVITATION Trial.

Authors:  Takuhiro Shirakawa; Koichiro Fujisue; Shinichi Nakamura; Nobuyasu Yamamoto; Shuichi Oshima; Toshiyuki Matsumura; Ryusuke Tsunoda; Nobutaka Hirai; Shunichi Koide; Shinji Tayama; Koichi Kikuta; Toyoki Hirose; Hideki Maruyama; Kazuteru Fujimoto; Ichiro Kajiwara; Tomohiro Sakamoto; Koichi Nakao; Naritsugu Sakaino; Yasuhiro Nagayoshi; Jun Hokamaki; Hideki Shimomura; Kenji Sakamoto; Eiichiro Yamamoto; Yasuhiro Izumiya; Koichi Kaikita; Seiji Hokimoto; Hisao Ogawa; Kenichi Tsujita
Journal:  J Atheroscler Thromb       Date:  2021-01-07       Impact factor: 4.394

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.